BullFrog AI has entered into exclusive, worldwide agreements with major US biomedical institutions to in-license assets for clinical development.
Our most advanced clinical candidate is a repositioned small molecule therapeutic, uniquely formulated for maximum utility against various cancers. The lead indication for this small molecule is glioblastoma, with subsequent programs anticipated for several other undisclosed indications. Our second drug candidate is a novel nucleic acid therapeutic for several interrelated liver diseases including cancer, obesity, non-alcoholic steatohepatitis (NASH), and non-alcoholic fatty liver disease (NAFLD). BullFrog’s third therapeutic program is an exclusive co-development project to design, generate, and validate a novel, precision-engineered oncolytic virus against colorectal cancer.
Our bfLEAP ™ AI/Unsupervised machine-learning platform identifies relationships and correlations from complex data structures. We are leveraging this capability to:
The bfLEAP™ platform offers the potential to rapidly identify previously unrecognized correlations and patterns within clinical data sets. This provides the opportunity to rescue failed drug candidates or repurpose drugs for new indications.
For drug candidates in development, our bfLEAP™ platform analyzes clinical trial data to identify correlates associated with favorable patient response to treatment, thereby informing inclusion/exclusion criteria and increasing the likelihood of success.
